Clinical trials: Stage A Prostate Cancer
Prostatic Neoplasms
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
Researchers have designed a study medicine called MK-5684 as a new way to treat prostate cancer. The purpose of this study is to learn what happens to MK-5684 in a person's body over time (a pharmacokinetic or PK study).
- Trial name
- NCT06554639
- Testing
- MK-5684, Prednisone, Fludrocortisone acetate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Liposarcoma, Prostate Cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
- Conditions
- Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- CDK4i (NCT04557449)
- Testing
- PF-07220060, Letrozole, Fulvestrant
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 430 people
- Sponsor
- Pfizer
Metastatic Castrate-sensitive Prostate Cancer
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level…
- Trial name
- LIBERTAS (NCT05884398)
- Testing
- Apalutamide, Androgen-deprivation Therapy (ADT)
- Where
- 93 sites in United States, Australia and 7 more
- Volunteers
- 420 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
- Trial name
- NCT06450106
- Testing
- STM-416p
- Where
- 4 sites in United States, Australia
- Volunteers
- 18 people
- Sponsor
- SURGE Therapeutics
Melanoma, Breast Cancer
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.
- Conditions
- Melanoma, Breast Cancer, Prostate Cancer
- Trial name
- PSX-X04 (NCT00636558)
- Testing
- CVA21
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Viralytics
Prostate Cancer
Atrasentan in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate…
- Trial name
- NCT00046943
- Testing
- atrasentan hydrochloride
- Where
- United States
- Sponsor
- Abbott
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Prostatic Neoplasms
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the…
- Trial name
- NCT06095089
- Testing
- JNJ-78278343, JNJ-87189401, Apalutamide
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 355 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer Patients
Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion
- Trial name
- NCT04664725
- Testing
- Repaglinide, Bupropion and SHR3680
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Castration-Resistant Prostatic Cancer
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen…
- Trial name
- NCT04404140
- Testing
- Ipatasertib, Atezolizumab, Docetaxel
- Where
- 9 sites in France, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Castration-resistant Prostate Cancer, CRPC
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of Seviteronel, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT02012920
- Testing
- Seviteronel: given orally once daily in 28 day cycles
- Where
- 23 sites in United States, Greece and 2 more
- Volunteers
- 200 people
- Sponsor
- Innocrin Pharmaceutical
Hormone Sensitive Prostate Cancer
A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
This is an open-label, multicenter, dose escalation and expansion Phase 1 study of SHR7280 in adult patients with hormone sensitive prostate cancer.
- Trial name
- NCT04995042
- Testing
- SHR7280
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer, Other Solid Tumors
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with…
- Conditions
- Prostate Cancer, Other Solid Tumors, Ewing Sarcoma
- Trial name
- NCT06926283
- Testing
- DXC008
- Where
- 4 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Metastatic Prostate Cancer
Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer
This is a Phase I/IIa study evaluating the safety and feasibility of [89Zr]Df-IAB2M as an immunoPET tracer for metastatic prostate cancer.
- Trial name
- IAB2M (NCT01923727)
- Testing
- [89Zr]Df-IAB2M
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- ImaginAb, Inc.
Prostate Cancer
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
This is a randomized, open-label and parallel phase I study to compare pharmacokinetics (PK), pharmacodynamics (PD) and safety of goserelin acetate sustained-release microspheres for injection (LY01005) and ZOLADEX® following…
- Trial name
- NCT05140512
- Testing
- LY01005, ZOLADEX® 3.6 mg
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Luye Pharma Group Ltd.
Prostate Cancer
A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer
GX301 is an experimental therapeutic vaccine directed against human telomerase, an enzyme playing an essential role in cancer cell proliferation.
- Trial name
- NCT02293707
- Testing
- GX301
- Where
- 24 sites in Italy, Spain
- Volunteers
- 99 people
- Sponsor
- Laboratoires Leurquin Mediolanum
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline